维得利珠单抗较抗肿瘤坏死因子药物降低老年IBD患者严重感染风险
该回顾性队列研究基于2014-2017年Medicare数据库,纳入65岁以上新使用抗TNF-α药物或维得利珠单抗的IBD患者(抗TNF组1152例,维得利珠单抗组480例),采用倾向评分加权比较安全性和有效性。结果显示维得利珠单抗组感染相关住院风险显著降低(aHR 0.47,95%CI 0.25-0.86),而两组在IBD相关住院、手术或新用糖皮质激素方面无显著差异。
要点
- 两组在IBD相关住院、手术及新用糖皮质激素方面无显著差异。
- 研究支持老年IBD患者优先考虑维得利珠单抗以降低感染风险。
核心结论
- 老年IBD患者使用维得利珠单抗相比抗TNF-α药物,感染相关住院风险更低。
- 两种药物在IBD相关住院、手术或新用糖皮质激素方面无显著差异。
研究设计与样本
- 回顾性队列研究,采用活性对照新用户设计,数据来自2014-2017年Medicare索赔数据库。
- 纳入65岁及以上新使用抗TNF-α药物或维得利珠单抗的IBD患者,抗TNF组1152例,维得利珠单抗组480例。
- 采用倾向评分加权控制混杂,计算调整风险比和95%置信区间。
主要发现
- 维得利珠单抗组感染相关住院的调整风险比为0.47(95%CI 0.25-0.86)。
- 两组在IBD相关住院、IBD相关手术及生物制剂启动后60天以上新用糖皮质激素方面无显著差异。
- 两队列中位年龄均为71岁,11%的患者年龄≥80岁;抗TNF组54%为克罗恩病,维得利珠单抗组57%为克罗恩病。
- 两队列在人口学、医疗利用或衰弱方面无显著差异,超过半数患者Charlson合并症指数≥2。
临床怎么用
- 对于65岁及以上IBD患者,选择生物制剂时可考虑维得利珠单抗以降低感染相关住院风险。
- 抗TNF-α药物与维得利珠单抗在IBD相关住院、手术和激素使用方面疗效相当,决策需综合感染风险与疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Despite the increased numbers of older adults with inflammatory bowel diseases (IBDs), there are few studies regarding the safety and effectiveness of IBD treatments in older adults. The aim of this study was to compare the safety and effectiveness of anti-tumor necrosis factor (TNF)-α agents and vedolizumab in older adults with IBD. METHODS: We conducted a retrospective cohort study using an active comparator, new-user design for adults age 65 years and older with IBD initiating anti-TNF-α agents and vedolizumab in the Medicare claims database from 2014 to 2017. The primary safety outcome was infection-related hospitalization (excluding intra-abdominal and perianal abscesses). Co-primary outcomes to estimate effectiveness were IBD-related hospitalization, IBD-related surgery, and new corticosteroid use 60 days or more after biologic initiation. We performed propensity score weighting to control for confounding and estimated adjusted hazard ratios and 95% confidence intervals using standardized morbidity ratio-weighted variables. RESULTS: We identified 1152 anti-TNF-α new users and 480 vedolizumab new users. The median age was 71 years in both cohorts and 11% were age 80 years or older. Crohn's disease patients comprised 54% of the anti-TNF-α cohort and 57% of the vedolizumab cohort. There was no significant difference in demographics, health care utilization, or frailty in both cohorts. More than half of both cohorts had a Charlson comorbidity index of 2 or higher. Vedolizumab users had a decreased risk of infection-related hospitalization (adjusted hazard ratio, 0.47; 95% confidence interval, 0.25-0.86). There was no significant difference in the outcomes approximating effectiveness. CONCLUSIONS: Older IBD patients treated with vedolizumab had a lower risk of infection-related hospitalization compared with those initiating anti-TNFs. We observed no difference in effectiveness defined by hospitalizations, surgery, or new corticosteroid use.
引用
- Kochar B, Pate V, Kappelman MD, et al. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults. Clin Gastroenterol Hepatol. 2021. PMID: 34481954. doi:10.1016/j.cgh.2021.08.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。